Pharmaceutical Executive-07-01-2017

Excitement over more new treatments for cancer and rare diseases is offset by cringing over prices.

Outlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.

With digital interventions in drug adherence regimes evolving to new levels of sophistication, Pharm Exec looks at the ongoing patient-behavior and privacy issues that still present significant challenges.

The rapid development and take-up of digital technology is forever changing the way pharma engages with patients-but the industry’s ultimate potential in tapping digital health to transform patient care hinges on embracing new shifts in culture and business strategy.

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared-including the role of the patient in the equation.

To gain better alignment of coverage and risk, evidence-based arguments are critical during the underwriting process.

Three messages that resonated from this year’s annual meeting of the Drug Information Association.

With the physician-access climate as daunting as ever for sales reps, four best practices in implementing artificial intelligence-based technology to help achieve engagement wins are explored.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator.

With healthcare professionals and patients now collecting much of their information online, there is new opportunity for “digital opinion influencers” to amplify traditional KOL messaging-or create their own.

Highlighting a sampling of new digital health devices that span the wide focus terrain in health technology.

Click the title above to open the Pharmaceutical Executive July 2017 issue in an interactive PDF format.

The recent EFPIA and EU health council conferences highlight the growing divisions-and resentments-between industry and governments in Europe.